agilon health, inc. (NYSE:AGL) Short Interest Up 5.1% in November

agilon health, inc. (NYSE:AGL) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 31,940,000 shares, an increase of 5.1% from the November 15th total of 30,390,000 shares. Based on an average daily trading volume, of 4,590,000 shares, the short-interest ratio is currently 7.0 days. Currently, 10.5% of the shares of the stock are short sold.

agilon health Stock Performance

AGL traded up $0.02 during trading on Monday, hitting $2.26. 1,684,808 shares of the company traded hands, compared to its average volume of 4,841,655. agilon health has a one year low of $1.50 and a one year high of $13.45. The stock’s fifty day moving average is $2.44 and its 200 day moving average is $4.38. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.06. The firm has a market cap of $931.16 million, a P/E ratio of -2.38 and a beta of 0.51.

agilon health (NYSE:AGL) last issued its earnings results on Thursday, November 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.19). agilon health had a negative net margin of 6.88% and a negative return on equity of 47.84%. The firm had revenue of $1.45 billion during the quarter, compared to the consensus estimate of $1.47 billion. During the same quarter in the previous year, the firm earned ($0.06) earnings per share. As a group, equities analysts predict that agilon health will post -0.52 EPS for the current fiscal year.

Insider Activity

In related news, Director John William Wulf bought 45,000 shares of the company’s stock in a transaction dated Thursday, December 5th. The stock was purchased at an average price of $2.18 per share, with a total value of $98,100.00. Following the completion of the acquisition, the director now owns 206,133 shares of the company’s stock, valued at $449,369.94. The trade was a 27.93 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Karen Mcloughlin purchased 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average cost of $2.20 per share, for a total transaction of $55,000.00. Following the completion of the acquisition, the director now directly owns 73,166 shares in the company, valued at $160,965.20. The trade was a 51.90 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 90,000 shares of company stock worth $198,100. Corporate insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. CWM LLC raised its stake in agilon health by 406.5% in the second quarter. CWM LLC now owns 9,081 shares of the company’s stock valued at $59,000 after purchasing an additional 7,288 shares in the last quarter. Nisa Investment Advisors LLC purchased a new position in shares of agilon health during the second quarter valued at about $60,000. Neo Ivy Capital Management bought a new position in shares of agilon health in the 2nd quarter worth approximately $1,006,000. Pallas Capital Advisors LLC purchased a new position in shares of agilon health in the 2nd quarter valued at approximately $77,000. Finally, Bank of New York Mellon Corp increased its stake in shares of agilon health by 18.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,108,921 shares of the company’s stock worth $7,252,000 after acquiring an additional 174,883 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on AGL shares. Royal Bank of Canada reiterated an “outperform” rating and set a $3.00 price target on shares of agilon health in a report on Tuesday, November 19th. TD Cowen lowered their price objective on agilon health from $6.00 to $2.00 and set a “hold” rating for the company in a research note on Monday, November 11th. Stifel Nicolaus cut their target price on shares of agilon health from $7.00 to $2.00 and set a “hold” rating on the stock in a research report on Tuesday, November 12th. Evercore ISI cut their price target on shares of agilon health from $7.00 to $4.00 and set an “in-line” rating on the stock in a report on Tuesday, October 8th. Finally, Citigroup decreased their target price on agilon health from $2.50 to $1.75 and set a “sell” rating for the company in a research note on Wednesday, November 13th. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.28.

About agilon health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.